Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

9004 Background: Capmatinib is a highly potent and selective MET inhibitor. Previous data of GEOMETRY mono-1 study showed a clinically meaningful overall response rate (ORR) and manageable toxicity profile in patients (pts) with METΔex14–mutated NSCLC who received 1–2 prior lines of treatment (tx) (Cohort 4) and in particular a high ORR in tx-naïve pts (Cohort 5b). Here we report the results in METΔex14–mutated NSCLC for duration of response (DOR) and progression-free survival (PFS) as well as the updated results for ORR. Methods: GEOMETRY mono-1 is a phase 2, multi-cohort, multicenter study evaluating capmatinib in pts with METΔex14-mutated or MET-amplified advanced NSCLC across 6 cohorts. Pts (≥18 yrs) with ECOG PS 0–1, ALK and EGFR wt, and stage IIIB/IV NSCLC were eligible. Pts with METΔex14 mutation (centrally confirmed) were assigned (regardless of MET amplification status/gene copy number) to Cohorts 4 and 5b and received capmatinib tablets 400 mg BID. Primary endpoint was ORR by Blinded Independent Review Committee (BIRC) per RECIST v1.1. Key secondary endpoint was DOR by BIRC. Results: As of Nov 08, 2018, 97 pts with METΔex14-mutated NSCLC (Cohort 4: 69 pts; Cohort 5b: 28 pts) were evaluable for efficacy. ORR (95% CI) by BIRC was 39.1% (27.6-51.6) in Cohort 4 and 71.4% (51.3-86.8) in Cohort 5b. While still immature at the time of this analysis, data on durability are promising: median DOR (95% CI) by BIRC was 9.72 (4.27-11.14) and 8.41 (5.55-NE) mo for Cohorts 4 and 5b, respectively; median PFS (95% CI) by BIRC was 5.42 (4.17-6.97) and 9.13 (5.52-13.86) mo for Cohorts 4 and 5b, respectively. Safety profile remains favourable and unchanged. Most common AEs (≥25% all grades) across all cohorts (n = 315), were peripheral edema (49.2%), nausea (43.2%), and vomiting (28.3%); majority of the AEs were grade 1/2. Final efficacy analysis (12-mo f-u on DOR) including biomarker data will be presented during meeting. Conclusions: These data confirm capmatinib to be a promising new treatment option for pts with METΔex14-mutated advanced NSCLC regardless of the line of therapy with deep and durable responses and manageable toxicity profile. Clinical trial information: NCT02414139.

• Publication year

  2019

• Venue

  Journal of Clinical Oncology

• Publication date

  2019-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2019.37.15_SUPPL.9004
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances

  2026cites this paper
• Responsiveness of different MET tumour alterations to type I and type II MET inhibitors

  2025cites this paper
• Autres cibles addictives (KRAS, RET, HER2, NTRK...)

  2024cites this paper
• Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions

  2024cites this paper
• Non-Small Cell Lung Cancer, Version 4.2024.

  2024cites this paper
• Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment

  2024cites this paper
• Prognostic Indicators for Precision Treatment of Non-Small Cell Lung Carcinoma

  2024cites this paper
• Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials

  2024cites this paper
• Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies

  2023cites this paper
• From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)

  2023cites this paper
• Pan-tumor analytical validation and osimertinib clinical validation in EGFR mutant non-small cell lung cancer, supporting the first next generation sequencing liquid biopsy in vitro diagnostic.

  2023cites this paper
• Optimized Detection of Unknown MET Exon 14 Skipping Mutations in Routine Testing for Patients With Non–Small-Cell Lung Cancer

  2023cites this paper
• MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing

  2023cites this paper
• An Observatory for the MET Oncogene: A Guide for Targeted Therapies

  2023cites this paper
• Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.

  2023cites this paper
• MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target

  2023cites this paper
• Autres cibles addictives (KRAS, RET, HER2, NTRK…)

  2023cites this paper
• Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC

  2022cites this paper
• Autres cibles addictives (KRAS, RET, HER2, NTRK…)

  2022cites this paper
• MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review

  2022cites this paper
• Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

  2022cites this paper
• Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

  2022cites this paper
• Non – Small Cell Lung Cancer, Version 3.2022

  2022cites this paper
• Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

  2022cites this paper
• Targeting MET amplification in Gastro-oesophageal (GO) malignancies and overcoming MET inhibitor resistance: challenges and opportunities

  2022cites this paper
• Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?

  2022cites this paper
• The Current Landscape for METex14 Skipping Mutations in Non–Small Cell Lung Cancer

  2022cites this paper
• Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer

  2021cites this paper
• Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer

  2021cites this paper
• Chemotherapy Knowledge Base Management in the Era of Precision Oncology.

  2021cites this paper
• Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in situ hybridization

  2021cites this paper
• Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management

  2021cites this paper
• Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non–Small-Cell Lung Cancer

  2021cites this paper
• Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment

  2021cites this paper
• A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors

  2021cites this paper
• Cancer bronchique non à petites cellules avec anomalies moléculaires actionnables (KRAS, BRAF, MET, fusions)

  2021cites this paper
• Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib

  2021cites this paper
• The role of MET in chemotherapy resistance

  2021cites this paper
• Systemic Therapy for Mutation-Driven NSCLC.

  2021cites this paper
• Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations

  2021influential citation
• Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors

  2021cites this paper
• Crizotinib in Patients With MET-Amplified NSCLC.

  2021cites this paper
• Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib

  2021cites this paper
• Uncommon targets in non-small cell lung cancer: everyone wants a slice of cake.

  2021cites this paper
• A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations

  2021cites this paper
• Paradigm shift in the management of metastatic nonsmall cell lung cancer

  2021cites this paper
• Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective

  2021cites this paper
• Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

  2021cites this paper
• MET Exon 14 Skipping Alterations in Non-small Cell Lung Carcinoma—Current Understanding and Therapeutic Advances

  2021cites this paper
• The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations

  2021cites this paper
• The role of multidisciplinary team and molecular tumor board in the treatment of a patient with lung cancer.

  2021cites this paper
• Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report

  2021cites this paper
• Lung cancer

  2021cites this paper
• Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer

  2020cites this paper
• Narrative review: mesenchymal-epithelial transition inhibitors—meeting their target

  2020cites this paper
• Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report

  2020cites this paper
• Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.

  2020cites this paper
• Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations

  2020cites this paper
• A Comperehensive Drug Repurposing Study for Covid19 Treatment: Novel Putative DHODH Inhibitors Show Association to Serotonin-Dopamine Receptors

  2020cites this paper
• OTT_A_219959 5691..5706

  2020cites this paper
• Tepotinib Ef fi cacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion

  2020cites this paper
• Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.

  2020cites this paper
• Anwendungen der FISH in der Diagnostik von Lungenkarzinomen

  2020cites this paper
• Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives

  2020cites this paper
• Non-small cell lung cancer targetable mutations: present and future

  2020cites this paper
• Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

  2020influential citation
• Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward

  2020cites this paper
• MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

  2020cites this paper
• Profils moléculaires des cancers bronchiques non à petites cellules à la Réunion

  2020cites this paper
• Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.

  2020cites this paper
• Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial

  2020cites this paper
• New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

  2020cites this paper
• Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations

  2020cites this paper
• Molecular Targets Beyond the Big 3.

  2020cites this paper
• Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors

  2020cites this paper
• Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients

  2020cites this paper
• Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives

  2020cites this paper
• Progress on treatment of MET signaling pathway in non-small cell lung cancer

  2020cites this paper
• Emerging therapeutic agents for advanced non-small cell lung cancer

  2020cites this paper
• Targeted Therapy for Non-Small Cell Lung Cancer

  2020cites this paper
• MET-dependent solid tumours — molecular diagnosis and targeted therapy

  2020cites this paper
• MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?

  2020cites this paper
• Targeting MET Dysregulation in Cancer.

  2020influential citation
• Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies

  2020cites this paper
• Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment

  2020cites this paper
• Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling

  2020cites this paper
• The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer

  2020cites this paper
• Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations

  2020cites this paper
• Molecular therapeutic targets in non-small cell lung cancer

  2020cites this paper
• Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date

  2020cites this paper
• A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib.

  2020cites this paper
• Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite

  2020influential citation
• Tepotinib efficacy in an NSCLC patient with brain metastasis harboring an HLA-DRB1-MET gene fusion.

  2020cites this paper
• Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations

  2020cites this paper
• Precision Medicine in Non-Small Cell Lung Cancer: Current Applications and Future Directions.

  2020cites this paper
• Role of imaging biomarkers in mutation-driven non-small cell lung cancer

  2020cites this paper
• Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.

  2020cites this paper
• Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis

  2020cites this paper
• Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.

  2020cites this paper
• “Lazarus effect” in patient affected by lung adenocarcinoma carrying EGFR, CTNNB1, MET exon 11 and PIK3CA mutations treated with gefitinib

  2020cites this paper